Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and Metformin
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 582
- Registration Number
- NCT01519674
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
Use of Somatropin in Turner Syndrome
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 57
- Registration Number
- NCT01518036
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Crawley, United Kingdom
Metabolism and Excretion of Liraglutide in Healthy Male Volunteers
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 7
- Registration Number
- NCT01517568
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands
Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH
Phase 1
Completed
- Conditions
- DiabetesHealthy
- Interventions
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 70
- Registration Number
- NCT01518166
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Uppsala, Sweden
Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome
Phase 4
Completed
- Conditions
- Turner SyndromeGenetic Disorder
- Interventions
- Drug: oestrogen
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 65
- Registration Number
- NCT01518062
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Alphen a/d Rijn, Netherlands
Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 18
- Registration Number
- NCT01517555
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Safety and Tolerability of Liraglutide in Healthy Japanese Male Volunteers
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: placebo
- First Posted Date
- 2012-01-24
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT01515592
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Effect of Liraglutide on Heart Frequency in Healthy Volunteers
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2012-01-24
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 64
- Registration Number
- NCT01516255
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Fargo, North Dakota, United States
Comparison of Two Liraglutide Formulations in Healthy Subjects
- First Posted Date
- 2012-01-24
- Last Posted Date
- 2015-01-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 22
- Registration Number
- NCT01515579
Evaluation of Safety and Parameters of Application Technique
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Delivery Systems
- Interventions
- Other: No treatment given
- First Posted Date
- 2012-01-24
- Last Posted Date
- 2016-11-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 4819
- Registration Number
- NCT01516242
- Locations
- 🇸🇰
Novo Nordisk Investigational Site, Bratislava, Slovakia
© Copyright 2025. All Rights Reserved by MedPath